Plasma beads loaded with Candida albicans cytosolic proteins impart protection against the fungal infection in BALB/c mice

Vaccine

Volumn 30, Issue 48, 2012, Pages 6851-6858

  Ahmad, Ejaj ^a   Fatima, Munazza T ^a   Saleemuddin, M ^a   Owais, M ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Candida albicans; Cytosolic protein; Liposomes; Plasma beads; Vaccine

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOSOLIC PROTEIN; FUNGAL PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4; LIPOSOME; NITRIC OXIDE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CANDIDA ALBICANS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIBODIES, FUNGAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, FUNGAL; CANDIDA ALBICANS; CANDIDIASIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HYPERSENSITIVITY, DELAYED; INTERFERON-GAMMA; INTERLEUKIN-4; LIPOSOMES; MICE; MICE, INBRED BALB C; PLASMA; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 84868213458     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.010     Document Type: Article

References (34)

1. Kobayashi S.D., Cutler J.E. Candida albicans hyphal formation and virulence: is there a clearly defined role?. Trends Microbiol 1998, 6(3):92-94.
2. Koh A.Y., Kohler J.R., Coggshall K.T., Van Rooijen N., Pier G.B. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 2008, 4:e35.
3. Hajjeh R.A., Sofair A.N., Harrison L.H., Lyon G.M., Arthington-Skaggs B.A., Mirza S.A., et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42(4):1519-1527.
4. Lopez-Berestein G., Bodey G.P., Fainstein V., Keating M., Frankel L.S., Zeluff B., et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989, 149(11):2533-2536.
5. Hazen K.C., Baron E.J., Colombo A.L., Girmenia C., Sanchez-Sousa A., del Palacio A., et al. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4 year global evaluation using disk diffusion. J Clin Microbiol 2003, 41(12):5623-5632.
6. Graybill J.R. The future of antifungal therapy. Clin Infect Dis 1996, 22(Suppl. 2):S166-S178.
7. Mochon A.B., Cutler J.E. Is a vaccine needed against Candida albicans?. Med Mycol 2005, 43(2):97-115.
8. Huang Y.C., Lin T.Y., Leu H.S., Wu J.L., Wu J.H. Yeast carriage on hands of hospital personnel working in intensive care units. J Hosp Infect 1998, 39(1):47-51.
9. Levy R., Segal E., Barr-Nea L. Systemic candidiasis in mice immunized with Candida albicans ribosomes. Mycopathologia 1985, 91:17-22.
10. Mencacci A., Torosantucci A., Spaccapelo R., Romani L., Bistoni F., Cassone A. A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity cytokine production, and anticandidal protection in mice. Infect Immun 1994, 62(12):5353-5360.
11. Mizutani S., Endo M., Ino-Ue T., Kurasawa M., Uno Y., Saito H. Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections. Antimicrob Agents Chemother 2000, 44:243-247.
12. Han Y., Kanbe T., Cherniak R., Cutler J.E. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun 1997, 65(10):4100-4107.
13. Ahmad E., Fatima M.T., Owais M., Saleemuddin M. Beaded plasma clot: a potent sustained-release, drug-delivery system. Therap Deliv 2011, 2(5):573-583.
14. Mallick A.I., Singha H., Khan S., Anwar T., Ansari M.A., Khalid R., et al. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. Vaccine 2007, 25(46):7873-7884.
15. Syed F.M., Khan M.A., Nasti T.H., Ahmad N., Mohammad O. Antigen entrapped in the escheriosomes leads to the generation of CD4(+) helper and CD8(+) cytotoxic T cell response. Vaccine 2003, 21(19-20):2383-2393.
16. Owais M., Gupta C.M. Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur J Biochem 2000, 267(13):3946-3956.
17. Buchanan K.L., Murphy J.W. Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun 1993, 61(7):2854-2865.
18. Ding A.H., Nathan C.F., Stuehr D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988, 141(7):2407-2412.
19. Fidel P.L., Lynch M.E., Sobel J.D. Candida specific Th1 type responsiveness in mice with experimental vaginal candidiasis. Infect Immun 1993, 61(10):4202-4207.
20. Xin H., Dziadek S., Bundle D.R., Cutler J.E. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci USA 2008, 105(36):13526-13531.
21. Han Y., Cutler J.E. Antibody response that protects against disseminated candidiasis. Infect Immun 1995, 63:2714-2719.
22. Wagner R.D., Vazquez-Torres A., Jones-Carson J., Warner T., Balish E. B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis. J Infect Dis 1996, 174(3):589-597.
23. Casadevall A., Pirofski L.A. Feasibility and prospects for a vaccine to prevent cryptococcosis. Med Mycol 2005, 43(8):667-680.
24. Espuelas S., Irache J.M., Gamazo C. Synthetic particulate antigen delivery systems for vaccination. Immunologia 2005, 24(2):208-223.
25. Senderoff R.I., Kontor K.M., Heffernan J.K., Clarke H.J., Garrison L.K., Kreilgaard L. Aqueous stability of recombinant human thrombopoietin as a function of processing schemes. J Pharm Sci 1996, 85(7):749-752.
26. Henriksen-Lacey M., Korsholm K.S., Andersen P., Perrie Y., Christensen D. Liposomal vaccine delivery systems. Expert Opin Drug Deliv 2011, 8(4):505-519.
27. Seder R.A., Paul W.E. Acquisation of lymphokine producing phenotype by CD4+ T cells. Annu Rev Immunol 1994, 12:635-673.
28. Vonk A.G., Netea M.G., van der Meer J.W., Kullberg B.J. Host defense against disseminated Candida albicans infection and implications for antifungal immunotherapy. Expert Opin Biol Ther 2006, 6(9):891-903.
29. Palmer R.M., Ashton D.S., Moncada S. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature 1988, 333(6174):664-666.
30. Hasbold J., Hong J.S., Kehry M.R., Hodgkin P.D. Integrating signals from IFN-γ and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a. J Immunol 1999, 163:4175-4181.
31. Huffnagle G.B., Lipscomb M.F., Lovchik J.A., Hoag K.A., Street N.E. The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol 1994, 55(1):35-42.
32. Agrewala J.N., Wilkinson R.J. Differential regulation of Th1 and Th2 cells by p 91-110 and p 21-40 peptides of the 16-kD alpha-crystallin antigen of Mycobacterium tuberculosis. Clin Exp Immunol 1998, 114:392-397.
33. Agrewala J.N., Owais M., Gupta C.M., Mishra G.C. Antigen incorporation into liposomes results in the enhancement of IL-4 and IgG1 secretion: evidence for preferential expansion of Th-2 cells. Cytokines Mol Ther 1996, 2:59-65.
34. Delamarre L., Holcombe H., Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 2003, 198(1):111-122.